Nalaganje...
Setbacks and promises for drugs against Alzheimer's disease: As pharmaceutical companies are retreating from drug development for Alzheimer's, new approaches are being tested in academia and biotech companies
The withdrawal of pharmaceutical companies from developing drugs against Alzheimer's highlights the inherent difficulties in tackling this devastating disease. In the meantime, biotech companies and basic research explore new targets and drug combinations.[Image: see text]
Shranjeno v:
| izdano v: | EMBO Rep |
|---|---|
| Glavni avtor: | |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
John Wiley and Sons Inc.
2018
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6123640/ https://ncbi.nlm.nih.gov/pubmed/30150324 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15252/embr.201846714 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|